Literature DB >> 1704384

Binding of S protein by Neisseria gonorrhoeae and potential role in invasion.

R J Arko1, C Y Chen, W O Schalla, S K Sarafian, C L Taylor, J S Knapp, S A Morse.   

Abstract

An agglutination assay was used to examine the binding of purified human S protein (vitronectin, serum spreading factor) to 201 clinical isolates of Neisseria gonorrhoeae. Strains belonging to the protein IA serovars were significantly (P less than 0.001) more reactive in agglutination tests with human S protein and were more serum resistant than strains belonging to the protein IB serovars. The strains from patients with disseminated infections belonged predominantly to the IA serovar (19 of 23) and, with the exception of IA-4 and certain IB serovars, avidly agglutinated with S protein. The serovar IA-4 and IB strains isolated from joint or cerebrospinal fluid failed to agglutinate with S protein and appeared to be less serum resistant than most other IA isolates. Cysteine hydrochloride or 2-mercaptoethanol inhibited agglutination of S protein and a more than twofold increase in resistance to killing by fresh human serum following preincubation with S protein; the serum-sensitive parent strain did not agglutinate S protein, and serum resistance was not increased following preincubation with this protein. Binding of S protein by gonococci may represent a novel pathogenic mechanism that can contribute to serum resistance.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1704384      PMCID: PMC269705          DOI: 10.1128/jcm.29.1.70-75.1991

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  27 in total

Review 1.  New perspectives in cell adhesion: RGD and integrins.

Authors:  E Ruoslahti; M D Pierschbacher
Journal:  Science       Date:  1987-10-23       Impact factor: 47.728

2.  Specific binding of the human S protein (vitronectin) to streptococci, Staphylococcus aureus, and Escherichia coli.

Authors:  G S Chhatwal; K T Preissner; G Müller-Berghaus; H Blobel
Journal:  Infect Immun       Date:  1987-08       Impact factor: 3.441

3.  SC5b-7, SC5b-8 and SC5b-9 complexes of complement: ultrastructure and localization of the S-protein (vitronectin) within the macromolecules.

Authors:  K P Preissner; E R Podack; H J Müller-Eberhard
Journal:  Eur J Immunol       Date:  1989-01       Impact factor: 5.532

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  A recombinant molecule from a disseminating strain of Neisseria gonorrhoeae that confers serum bactericidal resistance.

Authors:  W M McShan; R P Williams; R A Hull
Journal:  Infect Immun       Date:  1987-12       Impact factor: 3.441

6.  Modification by sialic acid of Neisseria gonorrhoeae lipooligosaccharide epitope expression in human urethral exudates: an immunoelectron microscopic analysis.

Authors:  M A Apicella; R E Mandrell; M Shero; M E Wilson; J M Griffiss; G F Brooks; C Lammel; J F Breen; P A Rice
Journal:  J Infect Dis       Date:  1990-08       Impact factor: 5.226

7.  Serovars and serum resistance of Neisseria gonorrhoeae from disseminated and uncomplicated infections.

Authors:  J A Morello; M Bohnhoff
Journal:  J Infect Dis       Date:  1989-12       Impact factor: 5.226

8.  The heparin binding domain of S-protein/vitronectin binds to complement components C7, C8, and C9 and perforin from cytolytic T-cells and inhibits their lytic activities.

Authors:  J Tschopp; D Masson; S Schäfer; M Peitsch; K T Preissner
Journal:  Biochemistry       Date:  1988-05-31       Impact factor: 3.162

9.  Immunoglobulin G antibodies directed against protein III block killing of serum-resistant Neisseria gonorrhoeae by immune serum.

Authors:  P A Rice; H E Vayo; M R Tam; M S Blake
Journal:  J Exp Med       Date:  1986-11-01       Impact factor: 14.307

10.  In vitro and in vivo modification of Neisseria gonorrhoeae lipooligosaccharide epitope structure by sialylation.

Authors:  R E Mandrell; A J Lesse; J V Sugai; M Shero; J M Griffiss; J A Cole; N J Parsons; H Smith; S A Morse; M A Apicella
Journal:  J Exp Med       Date:  1990-05-01       Impact factor: 14.307

View more
  9 in total

1.  Vitronectin mediates internalization of Neisseria gonorrhoeae by Chinese hamster ovary cells.

Authors:  T D Duensing; J P van Putten
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

2.  Binding of vitronectin to opa-expressing Neisseria gonorrhoeae mediates invasion of HeLa cells.

Authors:  O G Gómez-Duarte; M Dehio; C A Guzmán; G S Chhatwal; C Dehio; T F Meyer
Journal:  Infect Immun       Date:  1997-09       Impact factor: 3.441

3.  A Novel Factor H-Fc Chimeric Immunotherapeutic Molecule against Neisseria gonorrhoeae.

Authors:  Jutamas Shaughnessy; Sunita Gulati; Sarika Agarwal; Magnus Unemo; Makoto Ohnishi; Xia-Hong Su; Brian G Monks; Alberto Visintin; Guillermo Madico; Lisa A Lewis; Douglas T Golenbock; George W Reed; Peter A Rice; Sanjay Ram
Journal:  J Immunol       Date:  2016-01-15       Impact factor: 5.422

4.  Low levels of vitronectin and clusterin in acute meningococcal disease are closely associated with formation of the terminal-complement complex and the vitronectin-thrombin-antithrombin complex.

Authors:  K Høgåsen; T E Mollnes; P Brandtzaeg
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

5.  Identification and therapeutic potential of a vitronectin binding region of meningococcal msf.

Authors:  Darryl J Hill; Natalie J Griffiths; Elena Borodina; Clio A Andreae; Richard B Sessions; Mumtaz Virji
Journal:  PLoS One       Date:  2015-03-31       Impact factor: 3.240

6.  Pseudomonas aeruginosa Uses Dihydrolipoamide Dehydrogenase (Lpd) to Bind to the Human Terminal Pathway Regulators Vitronectin and Clusterin to Inhibit Terminal Pathway Complement Attack.

Authors:  Teresia Hallström; Melanie Uhde; Birendra Singh; Christine Skerka; Kristian Riesbeck; Peter F Zipfel
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

Review 7.  Meningococcal disease and the complement system.

Authors:  Lisa A Lewis; Sanjay Ram
Journal:  Virulence       Date:  2013-10-08       Impact factor: 5.882

8.  Conserved Patterns of Microbial Immune Escape: Pathogenic Microbes of Diverse Origin Target the Human Terminal Complement Inhibitor Vitronectin via a Single Common Motif.

Authors:  Teresia Hallström; Birendra Singh; Peter Kraiczy; Sven Hammerschmidt; Christine Skerka; Peter F Zipfel; Kristian Riesbeck
Journal:  PLoS One       Date:  2016-01-25       Impact factor: 3.240

9.  Complement Inhibitors Vitronectin and Clusterin Are Recruited from Human Serum to the Surface of Coronavirus OC43-Infected Lung Cells through Antibody-Dependent Mechanisms.

Authors:  Candace R Fox; Griffith D Parks
Journal:  Viruses       Date:  2021-12-24       Impact factor: 5.048

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.